CytomX Therapeutics, Inc. (CTMX) Insider Sells $177,566.34 in Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 9,562 shares of CytomX Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $18.57, for a total value of $177,566.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of CytomX Therapeutics, Inc. (NASDAQ CTMX) traded up 21.53% on Wednesday, hitting $23.09. The company’s stock had a trading volume of 3,353,455 shares. The stock has a 50-day moving average price of $16.92 and a 200 day moving average price of $15.62. The firm’s market cap is $851.26 million. CytomX Therapeutics, Inc. has a one year low of $9.85 and a one year high of $24.67.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The firm had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $4.95 million. Equities research analysts predict that CytomX Therapeutics, Inc. will post ($1.49) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “CytomX Therapeutics, Inc. (CTMX) Insider Sells $177,566.34 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/04/cytomx-therapeutics-inc-ctmx-insider-sells-177566-34-in-stock.html.
Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in shares of CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the period. First Quadrant L P CA purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $160,000. Goldman Sachs Group Inc. purchased a new stake in shares of CytomX Therapeutics in the 1st quarter valued at approximately $190,000. Cubist Systematic Strategies LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $174,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of CytomX Therapeutics in the 1st quarter valued at approximately $206,000. 59.97% of the stock is owned by institutional investors and hedge funds.
Several research firms recently commented on CTMX. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Nomura lifted their price target on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $30.00 price target (up previously from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $32.67.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.